KalVista Pharmaceuticals (KALV) Other Non-Current Liabilities (2014 - 2024)
KalVista Pharmaceuticals recorded quarterly Other Non-Current Liabilities of $99.9 million in Q4 2024, up 4268.43% quarter-over-quarter from $2.3 million in Q1 2015.
KalVista Pharmaceuticals' Other Non-Current Liabilities history runs 3 years deep, the most recent figure standing at $99.9 million for Q4 2024.
- In Q4 2024, Other Non-Current Liabilities changed N/A year-over-year to $99.9 million; the TTM figure through Dec 2024 stood at $99.9 million (changed N/A YoY), while the FY2014 annual figure was $1.5 million, changed N/A from the prior year.
- Other Non-Current Liabilities came in at $99.9 million for Q4 2024 at KalVista Pharmaceuticals, up from $2.3 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $99.9 million in Q4 2024 to a low of $99.9 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 99.91 Mn |
| Mar 31, 2015 | 2.29 Mn |
| Dec 31, 2014 | 1.50 Mn |